DIA
Drug Information Association

Call for Abstracts

"Emeralds of Experience" presentations

DUE BY SEPTEMBER 17, 2007

CLINICAL TRIAL DISCLOSURE

learning the landscape and reading the roadmap

November 13-14, 2007 | Hyatt Regency Bonaventure Conference Center and Spa, Weston, FL, USA

For further information, contact
Ellen Diegel, Program Manager
Phone +1.215.442.6158 / Fax +1.215.442.6199
Ellen.Diegel@diahome.org

This conference will provide practical, pharmaceutical and biotech company-based experience/advice and a hands-on conference venue for complying with worldwide regulations for public disclosure of clinical trial information. Individuals delivering this conference work inside the industry ensuring company compliance with laws and regulations governing the public disclosure of clinical trial information. Knowledge gained from industry-driven experience cannot be overstated.

This Event is Co-located with 4 other DIA Conferences for Added Networking Opportunities!

5 Co-located Events

- Publication Writing and Building Partnerships
- DIA Outsourcing Summit
- *PMI Pharmaceutical SIG/DIA PM SIAC Joint Conference:* The Future of Pharmaceutical Project Management – Is a Paradigm Shift Needed?
- Winning Strategies for Achieving a Quality EDC Clinical Trial Process: Sponsor/CRO, Investigator, IRB Approver and IT/IS

WHO SHOULD ATTEND

Those who will benefit from attending this program include:

- Clinical trial sponsors
- Independent investigators
- Biotechnology researchers
- Investigator site personnel
- Regulatory affairs personnel
- Medical communications groups
- Pharmaceutical industry and academic clinical researchers
- Clinical research and development departments
- Investigational review boards/ethics committees
- Clinical quality assurance professionals

See page 5 for Suggested Abstract Topics and Abstract Submission Guidelines

THIS PROGRAM WAS DEVELOPED BY THE **GOOD CLINICAL PRACTICES AND QUALITY ASSURANCE CLINICAL TRIAL DISCLOSURE WORKING GROUP** AND THE **CLINICAL RESEARCH, REGULATORY AFFAIRS,** AND **MEDICAL WRITING** SPECIAL INTEREST AREA COMMUNITIES

SIAC

VISIT WWW.DIAHOME.ORG FOR A COMPLETE SCHEDULE OF EVENTS!

DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044, USA tel: +1-215-442-6100 fax: +1-215-442-6199 email: dia@diahome.org

Continuing Education

The Drug Information Association (DIA) has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1620 I Street, NW, Suite 615, Washington, DC 20006. The DIA has awarded up to 1.1 continuing education units (CEUs) to participants who successfully complete this program.

To receive a statement of credit, please visit www.diahome.org. Detailed instructions on how to complete your credit request and download your certificate will be provided onsite.

Disclosure Policy: It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosure will be included in the course materials.

Learning Objectives: At the conclusion of this conference, participants should be able to:

- Name the major stakeholders influencing policymaking regarding the disclosure of clinical trial information
- Apply for a ClinicalTrials.gov protocol registration account
- Describe how, where, and when to publicly register a clinical trial and to post clinical trial results
- Plan a clinical trial disclosure process appropriate for their company use
- Differentiate relevant differences between major regulations, recommendations, and guidelines worldwide
- Discuss the required, proposed and voluntary requirements for clinical trial registration in the United States and other countries described in the workshop
- Describe the clinical trial lifecycle and the relevance to clinical trial disclosure
- Explain the relationship between registration and the trial publication plan
- Describe processes for ensuring the company is prepared for audit

Special 5-in-1 Plenary Session!

MONDAY • NOVEMBER 12

4:00-6:00 PM REGISTRATION

TUESDAY • NOVEMBER 13

7:30-8:15 AM REGISTRATION AND CONTINENTAL BREAKFAST

8:15-8:30 AM WELCOME AND OPENING REMARKS

8:30-9:15 AM *Plenary Session*

Join your colleagues from all 5 conferences during this special plenary session featuring keynote speaker **Harold Glass, PhD,** followed by a spirited Q&A session.

Added Feature!

Shared refreshment breaks, luncheons, and networking reception allow for extensive multidisciplinary networking opportunities among attendees

Keynote Address

DRUG DEVELOPMENT AS A BUSINESS: THE ROLE OF OUTSOURCING

Harold Glass, PhD, Professor, Health Policy, University of the Sciences in Philadelphia; President, TTC, LLC

Pharmaceutical drug development is part of a distinctive global business, distinguished by: the interaction of health care equity with the role of the market in health care delivery, contractors as customers, and the very large amounts spent on R&D. Outsourced costs such as CRO contracts and clinical grants represent a very large portion of all drug development spending. Pharmaceutical professionals involved in outsourced activities need to understand the role that business plays, and does not play, in the entire process, as well as how the major actors involved need to interact with one another.

Professor Harold E. Glass has more than twenty-five years' international experience in business and in the pharmaceutical industry. He is professor of health policy at the University of the Sciences in Philadelphia (USP). USP has a long legacy in the pharmaceutical industry dating back to University's founding in 1821, counting among its distinguished graduates such industry giants as Lilly, Wyeth, Rorer, Smith, Kline, Burroughs, Wellcome, Warner, Lambert, McNeil and many others. He is also senior research fellow at the Centre for Evidence Based Policy at Queen Mary, University of London.

Dr. Glass holds a MSc (Econ.) from the London School of Economics and a PhD from the University of North Carolina. He has served on the faculties of the University of North Carolina and University of Zurich, and has published widely in the areas of business strategy and drug development. Professor Glass is the founder of DataEdge, LLC, which he sold in 2001 to IMS Health. DataEdge was a company focusing on drug development and pharmaceutical marketing.

9:15-9:45 AM **Q&A Session with Keynote Speaker**

9:45-10:15 AM **REFRESHMENT BREAK**

Program Agenda for Clinical Trial Disclosure

10:15-10:30 AM **WELCOME FROM PROGRAM CHAIRPERSONS**

Barbara Godlew, RN
Associate Director, Publication
Coordination and Transparency Compliance
Exploratory Development Communications
Novartis Pharmaceuticals Corporation

Pamela Rose, RN, BSN, ASQ-CMQOE
Director
Clinical Trial Information Registries
TAP Pharmaceutical Products Inc.

10:30 AM-12:00 PM **SESSION 1**

Clinical Trial Landscape and Lifecycle: The Relationship between Disclosure and the Trial Publication Plan

CHAIRPERSONS

Barbara Godlew, RN

Robert Paarlberg, MS
Director, Global Regulatory Policy and Intelligence, UCB, Inc.

The relationship between clinical trial disclosure and the publication plan for congress abstracts/posters and completed study manuscript are closely intertwined. This session will examine some of the aspects clinical teams should consider when writing a study protocol as well as identifying key stakeholders to include in the publication planning process. Attendees will also gain knowledge on how the patients, families, and advocates view public disclosure of clinical trial protocols and results and how public disclosure may impact publication planning.

From the Editor's Desk: How Much is Too Much?
Paul W. Ladenson, MD
Editor-in-Chief, The Journal of Clinical Endocrinology & Metabolism, The Endocrine Society

Landscapes and Lifecycles: From the Perspective of the Publication Plan
Barbara Godlew, RN
Robert Paarlberg, MS

The Path Towards Access and Transparency: The Patients' Point of View
Pat Furlong
President, Parent Project Muscular Dystrophy

12:00-1:30 PM **LUNCHEON**

1:30-3:00 PM **SESSION 2**

Stakeholder Street Maps: A Worldwide Overview to Clinical Trial Disclosure

CHAIRPERSONS

Gerard Lynch
Global Manager, AstraZeneca Clinical Trials Website

Michael Rubison, PhD
Senior Director, Global Medical Research and Registration, Abbott Laboratories

This session provides an introduction to the major themes of the conference and provides an overview of the laws and policies associated with transparency of clinical trial registration and results disclosure. This overview will include US federal and state legislation, international policies and institutional agreements for both required and voluntary compliance, and the key issues that have driven clinical trial transparency. The international research and regulatory community has responded with a large array of databases and database standards proposed by international, national, regional healthcare and regulatory groups, pharmaceutical companies, academic institutions, professional societies, patient advocate and therapeutic specialty groups.

Key Milestones and Issues: A Chronological History of Clinical Trial Disclosure
Gerard Lynch
Michael Rubison, Phd

Understanding a New Street Map: FDA Revitalization Act and Clinical Trial Disclosure from a Legislature's Point of View
Speaker Invited

3:00-3:30 PM **REFRESHMENT BREAK**

3:30-5:00 PM **SESSION 3**

After the Trial is Completed: What, When, Where, and How to Post Trial Results

CHAIRPERSONS

Tracy Beck, PhD
Global Medical Business Office Consultant; CTR Results Gatekeeper, Eli Lilly and Company

Milen Vrabevski, MD
Medical Director/CEO, Comac Medical Ltd.

The biopharmaceutical industry has used clinical trial registries and results databases as one way to increase clinical trial transparency and public trust. Up until recently, the emphasis has been on registering trials at initiation, but now the focus has shifted towards disclosing results. This session will examine external stakeholders who are shaping the landscape of trial disclosure and what potholes to look out for. Attendees will learn what, when, and how to post results summaries, as well as how to avoid risks of off-label promotion when creating the summaries for public disclosure.

Brief Overview of Current Requirements for Posting Results
Pamela Rose, RN, BSN, ASQ-CMQOE

What, Where, and How to Post Results
Tracy Beck, PhD

How to Avoid the Risks of Off-label Promotion in Results Summaries
Bob Naidus, JD
Senior Pharmaceutical Counsel, Novartis Pharmaceuticals Corporation

5:30-6:45 PM **NETWORKING RECEPTION**

Sponsored by the **Good Clinical Practices and Quality Assurance Clinical Trial Disclosure Working Group** and the **Clinical Research, Regulatory Affairs and Medical Writing** Special Interest Area Communities

WEDNESDAY • NOVEMBER 14

7:30-8:30 AM REGISTRATION AND CONTINENTAL BREAKFAST

8:30-10:00 AM **SESSION 4**

Reading and Following the Road Map: Public Registration of Clinical Protocol Information

CHAIRPERSONS

Barbara Godlew, RN

Maureen Strange
Associate Medical Business Operations Consultant; CTR Initiated Gatekeeper, Eli Lilly and Company

Passed, pending, and proposed clinical trial registry legislation provides an array of confusing and sometimes conflicting articles and

requirements for both the end users and the registry administrators. This session will provide attendees with clarity on recent developments in federal legislation and challenges the staff at the National Library of Medicine face in complying with the requirements. Attendees will also gain knowledge in the functional use of ClinicalTrials.gov as we build a record in the registry, step-by-step, and answer audience questions during this process.

Finding and Unfolding the Map: Legislation Surrounding ClinicalTrials.gov
Rebecca Williams, PharmD
Assistant Director, ClinicalTrials.gov, National Library of Medicine

YES! You *Can* Register a Trial to ClinicalTrials.gov without a Global Positioning System and We'll Show You How !!!
Annice Bergeris
Information Research Specialist, National Library of Medicine
(assistance provided by Barbara Godlew and Maureen Strange)

10:00-10:30 AM **REFRESHMENT BREAK**

10:30 AM-12:00 PM **SESSION 5**

Herding Cats through Canyons: Developing a Company Process for Public Disclosure

CHAIRPERSONS

Margaret M. Cobb, MD, PhD
Global Leader of J & J Clinical Registry, Johnson & Johnson Pharmaceutical Research & Development, LLC

Patricia Teden, MBA
Independent Consultant

Creating a business process that is accurate, predictable, and capable of meeting the changing needs for disclosing information about clinical trials in multiple study registries and results databases is difficult. Companies need to leverage their current clinical trial process, determine if the disclosure steps will be centralized or decentralized, determine how much to leverage technology, and decide whether, and how, to use outside resources. During this session, we will hear how a large pharma, a small biopharmaceutical company, and a device company developed their clinical trial disclosure business process.

Herding Big Pharma Cats …
Margaret M. Cobb, MD, PhD

Small Pharma: The Cats with Many Hats
Anthony K. Taylor, Sr.
Clinical Operations Coordinator, Targanta Therapeutics Corporation

A Device Company and Combination Products Perspective
Lisa Griffin Vincent, PhD, MA
Senior Director, Corporate Clinical Research & Development, Medtronic Inc.

12:00-1:30 PM **LUNCHEON**

1:30-3:00 PM **SESSION 6**

Are You Ready? Preparing for Audit of Clinical Trial Disclosures

CHAIRPERSONS

John C. McKenney, Sr.
President & CEO, SEC Associates Inc.

Pamela Rose, RN, BSN, ASQ-CMQOE

State of Maine regulations require that publicly disclosed clinical trial information must be "reliable, accurate and true." The FDA Revitalization Act bill currently pending in Congress declares that clinical trial registry and results database information "shall not be false or misleading in any particular." Finally, the IFPMA statement on clinical trial disclosure calls for companies to "establish a process of verification" and to "make public how they will adhere to" the standards defined in the statement. Collectively, these statements build a compelling argument for instituting a robust audit program to assess your organization's trial disclosures. This session includes an overview of the key components comprising a sound clinical trial disclosure audit. The highlight of the session consists of a panel discussion featuring industry professionals who have been audited or have conducted audits of clinical trial disclosures. Attendees are invited to come armed with their most pressing questions to pose to our panelists on this timely and critical topic. Participants will leave this session with increased understanding and appreciation of how to prepare for, and what to expect during, a clinical disclosure audit.

PANELISTS

- *Auditee Perspective*
  Shawn M. Pelletier
  Associate Director R&D Operations
  Bristol-Myers Squibb Company
  Valerie V. Phillips, MA
  Manager Clinical Trial Disclosure
  Pfizer Inc
- *Auditor Perspective*
  John C. McKenney, Sr.
  Beat E. Widler, PhD
  Global Head of Clinical Quality Assurance
  F. Hoffmann-La Roche

3:00-3:30 PM **REFRESHMENT BREAK**

3:30-5:00 PM **SESSION 7**

"Emeralds of Experience"

Avoiding Accidents: Clinical Trial Disclosure Lessons Learned

CHAIRPERSON

Mary Kuskin, RPh
Director, Regulatory Affairs, Pharmalink Consulting Inc.

The field of clinical trial disclosure has expanded dramatically in the last ten years. There has been a steady increase in the reach of stakeholders, regulations and experience on a global scale. The strategy for posting and maintaining clinical trial information finds a place in the overall development and lifecycle strategy for biopharmaceutical and medical device companies. This session will highlight individuals' experiences along this path to share the practical aspects of balancing regulation compliance with presentation of meaningful information on clinical trial databases.

5:00 PM CONFERENCE ADJOURNED

"Emeralds of Experience" Information

The Drug Information Association (DIA) is offering a unique opportunity for presenters at the DIA Clinical Trial Disclosure conference in Weston, FL.

A podium session will provide those in the clinical trial disclosure field an opportunity to share their successes, challenges, and "Emeralds of Experience" on various topics with their DIA Clinical Trial Disclosure colleagues. Participants can share their experiences and "emeralds" by developing a 15-minute presentation.

Suggested Abstract Topics:

- Stakeholder Street Maps: A Worldwide Overview to Clinical Trial Disclosure Law
- Reading and Following the Road Map: Public Registration of Clinical Protocol Information
- After the Trial is Completed: What, When, Where, and How to Post Trial Results
- Clinical Trial Landscape and Lifecycle: The Relationship between Registration and the Trial Publication Plan
- Herding Cats through Canyons: Developing a Company Process for Public Disclosure
- Are You Ready? Preparing for Audit of Public Disclosure Processes

The Clinical Trial Disclosure "Emeralds of Experience" session is scheduled for Wednesday, November 14, 2007 at 3:30 pm.

Those interested in participating in the 15-minute podium presentation session should submit an abstract on the topic and information that will be presented. Due to the limited time available for podium presentations, only 4 (four) "Emeralds" will be accepted. A subset of the program committee will review and select from the topics submitted, if necessary. For those interested in submitting a poster, authors should submit an abstract according to the **Guidelines for Abstract Submission** below.

DEADLINE FOR SUBMISSIONS IS SEPTEMBER 17, 2007.

ALL ENTRIES MUST BE SUBMITTED ONLINE.

http://www.diahome.org/DIAHOME/GetInvolved/AbstractSubmissionLauncher.aspx

Guidelines for Abstract Submission

All abstracts must be received by **September 17, 2007**. Authors of selected abstracts will be notified by **September 28, 2007.** Please provide the following information using the online abstract form:

PRIMARY TOPIC AREA

SPEAKER NAME (Degrees, job title)

AFFILIATION (Mailing address, phone number, fax number, eMail)

PRESENTATION TITLE

SUMMARY (approximately 2-3 sentences) suitable for inclusion in preliminary program, if selected

LEARNING OBJECTIVES (Please provide two learning objectives to inform the learner of what he/she should be able to do after attending your session.

ABSTRACT (300 words or less)

DISCLOSURE INFORMATION
All speakers must disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in an educational presentation, as well as any discussion of unlabeled or unapproved drugs or devices.

1. At time of electronic submission of abstracts, all speakers must complete the speaker disclosure section of the electronic submission form.
2. Preference will be given to submitted abstracts that address real-life applications and case studies.
3. Final PowerPoint presentation for all accepted abstracts will be due to DIA by **October 23, 2007** to be reviewed by the committee and included in the attendee registration packet. Should you choose to submit an abstract for consideration, please mark your calendars with this deadline.
4. Final PowerPoint presentations for all accepted abstracts may have a company logo on slide number one. Any company logo appearing on any other slides will be removed by DIA.
5. Time allotted for individual presentations will be approximately 15-20 minutes. Final timing will be determined by the session chair and based on the number of presentations selected for the session.
6. DIA will provide complimentary conference attendance for the selected presenter.
7. Please note: Only one presenter per presentation will be allowed. Any exceptions to this policy must be discussed with the DIA office in advance.

TRAVEL AND HOTEL The most convenient airport is Fort Lauderdale/Hollywood International Airport and attendees should make airline reservations as early as possible to ensure availability. The Hyatt Regency Bonaventure Conference Center and Spa is holding a block of rooms at the reduced rate below until October 22, 2007, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

Single $189 **Double $214**

Please contact the Conference Center by telephone at +1-954-616-1234 or +1-800-233-1234 and mention the DIA event. The hotel is located at 250 Racquet Club Road, Weston, FL 33326, USA.

UNITED AIRLINES & US AIRWAYS
Save through Area Pricing and Discount Fees

To obtain schedule information and the best fares, call United Airlines's Specialized Meeting Reservations Center at **1-800-521-4041**. ***Make sure you refer to Meeting ID Number 571AK.*** Dedicated reservationists are on duty 7 days a week from 8:00 AM to 10:00 PM EST.

This special offer applies to travel on domestic segments of all United Airlines, United Express, PED, and United code share flights (UA*, operated by US Airways, US Airways Express and Air Canada).

GROUP DISCOUNTS* Register 3 individuals from the same company and receive complimentary registration for a 4th! ***All 4 individuals must register and prepay at the same time – no exceptions***. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. **Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.**

▶ **To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.**

Participants with Disabilities: *DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.*

CLINICAL TRIAL DISCLOSURE

learning the landscape and reading the roadmap

Hyatt Regency Bonaventure Conference Center and Spa, Weston, FL, USA

NOVEMBER 13-14, 2007 | Event ID #07039

CALL FOR ABSTRACTS

"Emeralds of Experience" presentations

DUE BY **SEPTEMBER 17**

5 Co-located Events for Added Networking Opportunities!

- DIA Outsourcing Summit
- Publication Writing and Building Partnerships
- *PMI Pharmaceutical SIG/DIA PM SIAC Joint Conference:* The Future of Pharmaceutical Project Management – Is a Paradigm Shift Needed?
- Winning Strategies for Achieving a Quality EDC Clinical Trial Process

MEMBER EARLY BIRD Register by OCT. 23, 2007 **SAVE $175**

Register online or fax this page to +1-215-442-6199

DRUG INFORMATION ASSOCIATION
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595 USA

CONTACT & TABLETOP EXHIBIT INFORMATION

Attendees may visit the tabletop exhibits during the event and during receptions (if applicable).

Event information: Contact Ellen Diegel at the DIA office by telephone +1-215-442-6158, fax +1-215-442-6199 or email Ellen.Diegel@diahome.org.

Tabletop exhibit information: Contact Erin Gilliland, Exhibits Associate, at the DIA office by telephone +1-215-442-6149, fax +1-215-442-6199 or email Erin.Gilliland@diahome.org. For tabletop exhibit space, please check the box below.

❑ **To receive a tabletop exhibit application, please check.**

GROUP DISCOUNTS (not available online or on already discounted fees)

Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. *See page 5 for complete details.*

Registration Fees *If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee. Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.*

MEMBER EARLY-BIRD OPPORTUNITY *Available on nondiscount member fee only*	On or before OCT. 23, 2007	After OCT. 23, 2007
Member Fee	US $1165 ❑	US $1340 ❑

Join DIA now to qualify for the early-bird member fee! **www.diahome.org/en/Membership/AboutMembership/AboutMembership**

MEMBERSHIP
US $ 130 ❑

To qualify for the early-bird discount, registration form and accompanying payment must be received by the date above. Does not apply to government/academia/nonprofit members.

Nonmember Fee	US $1470 ❑

A one-year membership to DIA is available to those paying a NONMEMBER registration fee. If paying a nonmember fee, please indicate if you do, or do not, want membership.

I want to be a DIA member ❑ I do NOT want to be a DIA member ❑

Discount Fees	MEMBER	NONMEMBER*
Government (Full-time)	US $ 300 ❑	US $ 430 ❑
Charitable Nonprofit/Academia (Full-time)	US $ 675 ❑	US $ 805 ❑

**If paying a nonmember fee, please check one box above, indicating whether you want membership.*

CANCELLATION POLICY: On or before NOVEMBER 6, 2007

Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academia or Nonprofit (Member or Nonmember) = $100
Tutorial (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

❑ **I cannot attend but please keep me informed of DIA's future events.**
(requires completion of name, postal address and email address on this form)

REGISTRATION FORM

Do not remove mailing label. Please return this entire page. **07039**
PLEASE CONSIDER THIS FORM AN INVOICE

Please check the applicable category:
❑ Academia ❑ Government ❑ Industry ❑ CSO ❑ Student *(Call for registration information)*

Last Name Check if part of group registration ❑ First Name M.I.

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Address As required for postal delivery to your location Mail Stop

City State Zip/Postal Country

email Required for confirmation

Phone Number Fax Number Required for confirmation

Group Registrant #2 Last Name First Name Completed form required for each group registrant

Group Registrant #3 Last Name First Name Completed form required for each group registrant

Group Registrant #4 Last Name First Name Completed form required for each group registrant

PAYMENT OPTIONS

Register online at www.diahome.org or check payment method

❑ **CREDIT CARD** number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.

☐ Visa ☐ MC ☐ AMEX *Exp Date* _____

Card # _____

Name (printed) _____

Signature _____

❑ **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc, P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

❑ **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event I.D. # must be included on the transfer document to ensure payment to your account.